Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. 4

• Material Type: 博士論文
• ISSN: 1558-7673
• Title: Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
• Volume: 13 4
• Author/Editor: NODA, Satoshi
• Author Heading: NODA, Satoshi
• Publication, Distribution, etc.: Elsevier
• Publication Date: 2015-08
• Publication Date (W3CDTF): 2015-08
• Periodical title: Clinical Genitourinary Cancer
• Degree grantor/type: 滋賀医科大学
• Date Granted: 2015-09-09
• Date Granted (W3CDTF): 2015-09-09
• Dissertation Number: 甲第736号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第736号
• Text Language Code: eng
• Subject Heading: Individualized pharmacotherpy; Kidney cancer; Pharmacokinetics; Tolerability; Tyrosine kinase inhibitor
• Target Audience: 一般
• Note (General): Background:Sunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability.; Patients and methods:A retrospective, observational clinical study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib concentration in a steady state during the first cycle.; Results:The median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of thrombocytopenia, anorexia, and fatigue. Patients with ≥ 100 ng/mL total sunitinib (n = 8), compared with patients with < 100 ng/mL (n = 13), had a greater incidence of Grade ≥ 3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]). Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02).; Conclusion:Results of this study suggest that therapeutic drug monitoring of sunitinib could be useful for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is ≥ 100 ng/mL, to avoid unnecessary early discontinuation of treatment.; Thesis or Dissertation; 平成27年度; 10.1016/j.clgc.2015.01.007
• DOI: info:doi/10.1016/j.clgc.2015.01.007; https://doi.org/info:doi/10.1016/j.clgc.2015.01.007
• Persistent ID (NDL): info:ndljp/pid/9984840; https://dl.ndl.go.jp/pid/9984840
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2016-06-03T01:05:16+09:00
• Date Created (W3CDTF): 2017-02-17
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10422/11691; https://shiga-med.repo.nii.ac.jp/records/2917
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2017-07-03 再収集

2019-09-06 再収集

2023-07-18 再収集

2023-10-11 再収集